期刊
FASEB JOURNAL
卷 36, 期 10, 页码 -出版社
WILEY
DOI: 10.1096/fj.202200765R
关键词
cell death; ceramides; cytarabine; drug resistance; leukemia; myeloid; acute; models; animal; recurrence; signal transduction; standard of care; venetoclax
资金
- HHS | NIH | National Cancer Institute (NCI) [P01-CA171983, F99CA245802, P30-CA044579, F31-CA271809]
Research has shown that using a nanoscale delivery system for ceramide (CNL) can enhance the efficacy of venetoclax/cytarabine treatment in acute myeloid leukemia (AML) by reducing drug-resistant signaling pathways and increasing cell death.
Despite several new therapeutic options for acute myeloid leukemia (AML), disease relapse remains a significant challenge. We have previously demonstrated that augmenting ceramides can counter various drug-resistance mechanisms, leading to enhanced cell death in cancer cells and extended survival in animal models. Using a nanoscale delivery system for ceramide (ceramide nanoliposomes, CNL), we investigated the effect of CNL within a standard of care venetoclax/cytarabine (Ara-C) regimen. We demonstrate that CNL augmented the efficacy of venetoclax/cytarabine in in vitro, ex vivo, and in vivo models of AML. CNL treatment induced non-apoptotic cytotoxicity, and augmented cell death induced by Ara-C and venetoclax. Mechanistically, CNL reduced both venetoclax (Mcl-1) and cytarabine (Chk1) drug-resistant signaling pathways. Moreover, venetoclax and Ara-C augmented the generation of endogenous pro-death ceramide species, which was intensified with CNL. Taken together, CNL has the potential to be utilized as an adjuvant therapy to improve outcomes, potentially extending survival, in patients with AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据